Member Info for BuenaVista

Yes I remember the question also but I don't think the intention was that Avacta divert valuable resources to it, although that's the way CC and MM chose to interpret it, perhaps deliberately so as to limit and then reject the idea.

I don't think anyone suggested that Avacta should develop veterinary therapeutics themselves. That would be a preposterous idea! But the tech could have been licensed out to a veterinary research organisation, assuming the IP covered that.

At least when he's on here he's not out bothering nurses.

See what a social service we are providing by entertaining his spurious arguments and delusions of grandeur!

Just a reminder that Toukankahmoon is angry because he got spiked, twice.

Sterling work there B2H! And no ferry docks anywhere to be seen!

Tbf, I added the "Really, nothing more needs to be said." after inserting a - - - - - break line.

But, anyway... Really, nothing more needs to be said.

🥱

Just a reminder that Thornogson/NDN/Eggy has never been invested in Avacta and works for TW to undermine sentiment here with constant talk about his spurious 'half-life issue'.

As DanGB laid it out succintly:

Half life is not an issue with AVA6000/DOX.

It is an issue with exatecan.

It might be an issue with other payloads.

Down talking AVA6000 based on half-life is FUD.

And, although yet to be proven in clinic, Avacta now has the ability to tailor half-life to the payload if required.

- - - - -

Really, nothing more needs to be said. Nothing.

And the ToucanOfDoom account has posted 174 times, 68 of them through the bottom of a whisky glass.🥃🥴 Amazing!

😳Thorn/ToucanOfDoom said that?🤣🤣🤣

Probably thinks you're a nurse.

He hasn't got an average. Like Thornogson/NDN/Eggy, he hasn't got any shares, never did have. It's all make believe, the both of them, indivisible.

Just a reminder that the pub bore is just the person you turn tail on when you enter the pub.

As DanGB laid it out in simple language:

Half life is not an issue with AVA6000/DOX.

It is an issue with exatecan.

It might be an issue with other payloads.

Down talking AVA6000 based on half-life is FUD.

And, although yet to be proven in clinic, Avacta now has the ability to tailor half-life to the payload if required.

- - - - -

Really, nothing more needs to be said. Nothing.

Ah yes, the argument that nothing is worth developing unless it is perfect.

...And Hemo can cure blood cancers so Avacta should do nothing less than cure solid tumours argument... The Dunning-Kruger Kid srtikes again!🤣🤣🤣

Yes, it goes without saying. The half-life fantasist.

🤣🤣🤣 what a weirdo!

And he claims to be invested in Avacta with something like 10% to 25% of his £200,000 to £2.5m portfolio.

What a fantasist!

The ToucanOfDoom now jumping in on the 'half-life issue'...

There's really nothing special about Avacta having a Dun & Bradstreet D‑U‑N‑S Number, except that it does (now) have one. It is just a unique company identifier (a unique identifier for every unique company) for comapnies in all industrial sectors: https://www.dnb.co.uk/smb/duns.html

Here is the Zonsen PepLib pipeline: https://www.peplib.com/Product-Details/3.html - Nothing to see there really except to note that none of the 21 targets, of which 13 are in oncology, have even reached the IND stage.

Additionally, about the agreement with Novartis ( https://www.bioxconomy.com/partnering/double-take-novartis-signs-back-to-back-licensing-agreements ):

"Novartis has signed a global licensing deal with Chinese biopharmaceutical company Zonsen PepLib. The biotech is set to receive an upfront payment of $50 million in exchange for rights to an undisclosed peptide-based radiopharmaceutical cancer drug, which it has already developed internally. Novartis will also be responsible for the development and commercialization of the asset.

"“We have advanced this peptide asset internally and believe that Novartis, with its deep expertise and proven track record in radioligand therapies, is well-positioned to take the program forward and help translate our early work into a potential medicine for patients,” Lei Chen, cofounder of PepLib, said."

- - - - -

Novartis's FAP-2286 (Rofapitide tetraxetan), which is currently in Phase 1/2 clinical trials, has been noted in this thread. It contains a heptapeptide completely unrelated to Avacta's dipeptide in both structure and purpose: https://www.nature.com/articles/s41598-025-91716-3